ReNeuron Group PLC treats first patient in retinitis pigmentosa trial
The procedure involves a single injection of hRPC cells under the retina
Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 14 of 15
ReNeuron eyeing data rich period as it progresses four opportunities
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.
Archive
Proactive news summary: dotDigital, Image Scan Holdings, Pan African Resources, TyraTech and more.
Biotech group Scancell is to present an update on its immunotherapy technologies at the Biotech Capital Conference in London.
ReNeuron heads west to find new home in Wales
Stem cell specialist ReNeuron Group will start life in new facilities in Wales next month.
Archive
Proactive news summary: Avation PLC, Premier Oil, OPG Power Ventures and Real Good Food.
A round-up of news from the Proactive Investors universe.
ReNeuron gets notice of US cryptopreservation patent
ReNeuron is using cryopreservation technology in its CTX stem cell line
Archive
FTSE 100 bounces back, with blue-chips leading the way
Unusually, the majority of the big gains today were to be found among the FTSE 350 - especially the FTSE 100
Archive
Proactive news summary: African Potash, Alliance Pharma, Atlantic Coal, Challenger Acquisitions ...
A round-up of the day's company news from the small cap universe
ReNeuron reveals anti-cancer properties of cell line
Researchers found ReNeuron’s specially developed CTX cell line was able to “enrich” a set of these microRNAs with anti-cancer properties.
ReNeuron secures £2.1mln govt grant
The AIM listed biotech is already a world leader in the field and is currently using stems cells to treat stroke patients.
Archive
Proactive news summary: AFC Energy, Atlantis Resources, Brady, Chariot, Forte Energy, Noricum ...
The day's small cap news was dominated by the latest UK oil & gas licensing round.
ReNeuron establishes scientific advisory board
The board’s role is to advise on topics related to ReNeuron’s areas of activity
Investments and investor services
Proactive news highlights: IOG, Motif Bio, allergy Therapeutics, ReNeuron, Immupharma and more
Sunrise Resources, Optibiotix Health and ITM Power also had news out
UPDATE - ReNeuron's third trial gets underway, first in US
Fifteen patients will take part in the trial at the Massachusetts Eye and Ear Infirmary in Boston.
Week Ahead: MPC unlikely to rock the boat
The Bank of England's Monetary Policy Committee is expected to leave its base rate unchanged; the question is, how many committee members will vote for change?
Investments and investor services
Proactive news highlights: Tissue Regenix, ReNeuron, DiamondCorp, Cairn Energy and more
Stratmin Global, Tertiary Minerals and Fastjet also had news out on Friday
ReNeuron adds former Glaxo biotech veteran to board
For many years Dr owen held a research position at the Imperial Cancer Research Fund (now CR-UK).
ReNeuron set for progress over the next three years
Last month the company raised funds which will be used to drive ReNeuron’s existing therapeutic programmes through to 2019.
Investments and investor services
Proactive news summary: ATTRAQT, DekelOil, Magnolia, Mart Resources, Mosman, Mwana, Oilex, Ortac...
Energy firms dominated news flow in the Proactive firmament today
ReNeuron confirms £68.4mln Woodford-backed placing
Lauded fund manager Neil Woodford is among the investors backing the company through the placing.